UBS downgraded FMC (FMC) to Neutral from Buy with a price target of $38, down from $66. The firm no longer sees the potential for a 2025 market bounce in crop chemicals demand, and says FMC’s strategy pivot “now adds a degree of execution risk.” This will lead to sustained pressure on the shares near term, and potentially a structural de-rating as debates on diamide patents persist for years to come, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio